A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis

EGF-like growth factors control tumor progression, as well as evasion from the toxic effects of chemotherapy. Accordingly, antibodies targeting the cognate receptors, such as EGFR/ErbB-1 and the co-receptor HER2/ErbB-2, are widely used to treat cancer patients, but agents that target the EGF-like gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindzen, Moshit, Carvalho, Silvia, Starr, Alex, Ben-Chetrit, Nir, Pradeep, Chaluvally-Raghavan, Köstler, Wolfgang J., Rabinkov, Aaron, Lavi, Sara, Bacus, Sarah S., Yarden, Yosef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290749/
https://www.ncbi.nlm.nih.gov/pubmed/22105361
http://dx.doi.org/10.1038/onc.2011.518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290749/
https://www.ncbi.nlm.nih.gov/pubmed/22105361
http://dx.doi.org/10.1038/onc.2011.518

Ejemplares similares